MSB 3.21% $1.13 mesoblast limited

Cell Therapy News/Articles, page-17947

  1. 2,889 Posts.
    lightbulb Created with Sketch. 2045
    correct whytee

    first CRL questioned Efficacy , potency and other unknown CMC items.

    Second CRL questioned consistency of potency and other CMC items .

    But you know this.


    whadda reckon has changed this time ?

    Acknowledging efficacy for an unmet need - 4 year independent survival results - asked to resubmit

    Are your fingers crossed?


    Reg

    anon

    Last edited by reginaldp: 13/08/24
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.